Scarica l'app Stockscreener
5.932
0.50%
-0.028
Precedente Chiudi:
$5.96
Aprire:
$5.93
Volume 24 ore:
80,521
Relative Volume:
0.09
Capitalizzazione di mercato:
$325.53M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-3.5101
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
+6.65%
1M Prestazione:
-15.53%
6M Prestazione:
-31.05%
1 anno Prestazione:
+0.85%
Intervallo 1D:
$5.91
$6.03
Intervallo di 1 settimana:
$5.50
$6.175
Portata 52W:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.93 | 313.45M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.18 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.60 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.35 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
704.59 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
299.62 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Live market analysis of Candel Therapeutics Inc.Trade Analysis Report & Fast Moving Stock Trade Plans - Newser
Is a relief rally coming for Candel Therapeutics Inc. holders2025 Growth vs Value & Long-Term Growth Stock Strategies - Newser
What’s the recovery path for long term holders of Candel Therapeutics Inc.2025 Market Outlook & Daily Stock Trend Watchlist - Newser
Sector ETF performance correlation with Candel Therapeutics Inc.2025 Analyst Calls & AI Driven Price Predictions - Newser
Real time pattern detection on Candel Therapeutics Inc. stock2025 Stock Rankings & Low Drawdown Momentum Ideas - Newser
Advanced analytics toolkit walkthrough for Candel Therapeutics Inc.M&A Rumor & Safe Entry Trade Reports - Newser
Is Candel Therapeutics Inc. stock entering bullish territoryGold Moves & Free AI Powered Buy and Sell Recommendations - Newser
Applying Wyckoff theory to Candel Therapeutics Inc. stockWeekly Trade Analysis & Capital Efficiency Focused Ideas - Newser
Using Bollinger Bands to evaluate Candel Therapeutics Inc.Weekly Investment Report & Fast Momentum Entry Tips - Newser
Is Candel Therapeutics Inc. benefiting from interest rate changes2025 Technical Patterns & Daily Volume Surge Trade Alerts - theviewers.co.kr
What to expect from Candel Therapeutics Inc. in the next 30 daysCPI Data & AI Based Buy/Sell Signal Reports - Newser
Candel Therapeutics' Lease Extension: A Strategic Anchor for R&D and Investor Confidence in a Volatile Biotech Landscape - AInvest
Candel Therapeutics extends lease term to Aug 31, 2029 - MarketScreener
Candel Therapeutics Extends Lease Agreement in Needham - TipRanks
Chartists See Breakout Potential in Candel Therapeutics Inc.2025 Support & Resistance & Growth Oriented Trade Recommendations - beatles.ru
Candel Therapeutics Insider Ups Holding By 22% During Year - simplywall.st
Automated trading signals detected on Candel Therapeutics Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
Candel Therapeutics shares rise 3.42% after-hours following FDA's rejection of PTC Therapeutics' drug. - AInvest
Candel Therapeutics Advances with Promising Cancer Therapies - TipRanks
Bullish Candlestick Pattern Forms in Candel Therapeutics Inc.Price Action & AI Driven Price Predictions - classian.co.kr
Candel Therapeutics Posts Q2 2025 Loss, But History Suggests Strong Post-Earnings Recovery Potential - AInvest
How institutional ownership impacts Candel Therapeutics Inc. stockJuly 2025 Market Mood & AI Forecasted Entry/Exit Points - Newser
Candel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer Treatment - MSN
Candel Therapeutics Posts Loss in Q2 2025; Surprising Market Resilience Sparks Investor Interest - AInvest
Does Candel Therapeutics Inc. show high probability of rebound2025 Winners & Losers & AI Driven Stock Reports - Newser
Candel Therapeutics secures RMAT for prostate cancer – ICYMI - Proactive financial news
Candel Therapeutics reports Q2 EPS (9c) vs. (74c) last year - MSN
Candel Therapeutics Inc. Matches Institutional Buying Filter2025 Market Outlook & Long-Term Investment Growth Plans - newsyoung.net
Candel Therapeutics: Promising Pipeline Developments and Strategic Advancements Support Buy Rating - TipRanks
Candel eyes 2026 U.S. filing for CAN-2409 after Phase 3 success and FDA RMAT status - Proactive financial news
Candel Therapeutics’ CAN-2409: Promising Phase 3 Results and Market Potential - TipRanks
Candel Therapeutics shares fall 5.16% intraday despite positive clinical trial results and regulatory designations. - AInvest
Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Small cap wrap: Lancaster Resources, Candel Therapeutics, atai Life Sciences, Charbone Hydrogen... - Proactive financial news
Candel Therapeutics sees cash runway into 1Q27 - TipRanks
CCORF Maintains Candel Therapeutics(CADL.US) With Buy Rating, Maintains Target Price $25 - 富途牛牛
Candel Therapeutics Advances Prostate Cancer Therapy Filing After Successful Trial - AInvest
Candel Therapeutics advances toward prostate cancer therapy filing after trial success - Proactive financial news
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
Candel's Prostate Cancer Treatment Secures FDA Fast Track After Breakthrough Trial Results - Stock Titan
Can Candel Therapeutics Inc. be recession proofJuly 2025 Sentiment & Low Drawdown Investment Strategies - classian.co.kr
Can Candel Therapeutics Inc. grow without dilutionWeekly Gains Report & Long Hold Capital Preservation Plans - newsyoung.net
Candel Therapeutics Inc. Stages Intraday Comeback — Trend ChangeReal Trader Watchlist of Hot Stocks Released - beatles.ru
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
Candel Therapeutics shares fall 2.76% intraday after announcing clinical trial initiation for tecarfarin in dialysis patients. - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Candel Therapeutics Inc Azioni (CADL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
1.41%
7.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):